



Kilitch Drugs (India) Ltd.

Admin. Off. : 37, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088.
 • Tel. : +91-22-6121 4100 • Fax : +91-22-6703 1658
 Regd. Off. : C-301/2, M.I.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705. Maharashtra
 & Factory : • Tel. : +91-22-6514 4185 / 2768 0913 • Fax : +91-22-2768 0912
 • E-mail : info@kilitch.com • Website : www.kilitch.com

November 9, 2012

To,
 The Listing Department
 National Stock Exchange of India Limited
 Exchange Plaza, Plot no. C/1, G Block,
 Bandra-Kurla Complex
 Bandra (E), Mumbai - 400 051.

Respected Sir,

Scrip Code : KILITCH

Sub: OUTCOME OF THE BOARD MEETING HELD ON FRIDAY, NOVEMBER 9, 2012.


With reference to the above captioned subject, we wish to intimate your esteem exchange that as decided in the Meeting of the Board of Directors of the Company held on **Friday, November 9, 2012**, for which intimation was already given to you, it was decided:

- To adopt and approve the Unaudited (Provisional) Financial Results of the Company for the quarter ended 30th September 2012.

The above intimation is given to you for your record.

Thanking You,

Yours faithfully,
 For **KILITCH DRUGS (INDIA) LIMITED**


MUKUND MEHTA
MANAGING DIRECTOR.



KILITCH DRUGS INDIA LIMITED
Statement of Standalone and Consolidated Unaudited Financial Results for the Quarter and half year ended 30th September 2012

PART I

Particulars	STAND-ALONE						CONSOLIDATED					
	Unaudited			Audited			Unaudited			Audited		
	Quarter ended		Half year ended		Year ended		Quarter ended		Half year ended		Year ended	
	30th September 2012	30th June 2012	30th September 2011	30th September 2012	30th September 2011	31st March 2012	30th September 2012	30th June 2012	30th September 2011	30th September 2012	30th September 2011	31st March 2012
1 Income from operations												
(a) Net Sales/Income from operations (net of Excise)	589.44	1,481.43	3,281.58	2,070.87	6,311.01	10,685.99	650.96	1,543.19	3,340.19	2,194.15	6,419.19	10,796.35
(b) Other operating income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Income from Operations (Net)	589.44	1,481.43	3,281.58	2,070.87	6,311.01	10,685.99	650.96	1,543.19	3,340.19	2,194.15	6,419.19	10,796.35
2 Expenses												
(a) Cost of materials consumed	406.14	1,391.44	1,933.46	1,797.58	4,129.01	7,058.99	438.89	1,400.89	1,958.84	1,839.78	4,165.37	7,059.27
(b) Purchased of Stock-in-trade	0.00											
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	120.60	-119.54	-12.46	1.06	-296.33	135.13	122.87	-111.99	-12.46	11.04	-296.33	126.02
(d) Employee benefits expenses	60.20	59.23	131.52	119.43	245.08	499.78	99.39	95.43	191.44	194.82	337.33	844.48
(e) Depreciation and amortisation expenses	32.81	32.81	140.31	65.62	280.00	483.37	33.80	33.80	140.31	67.60	280.00	487.35
(f) Other expenses (Any item exceeding 10% of the expenses relating to continuing operations to be shown separately)	198.45	142.37	425.59	340.82	818.15	1,575.64	230.22	167.04	465.70	397.26	870.72	1,703.99
Total Expenses	818.20	1,506.34	2,618.82	2,324.51	5,176.91	9,752.91	925.27	1,585.23	2,743.83	2,510.50	5,357.09	10,021.09
Profit / (Loss) from operations before other income,												
3 finance costs and exceptional items (1-2)	-228.76	-24.88	662.76	-253.64	1,134.10	933.08	-274.31	-42.04	596.36	-316.35	1,062.10	775.26
4 Other Income	254.74	329.87	21.09	584.41	25.32	110.25	258.02	332.74	22.59	590.77	25.32	105.13
Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	25.98	304.79	683.85	330.77	1,159.42	1,043.33	-18.29	290.70	618.95	274.42	1,087.42	880.39
5 Finance Costs	4.19	2.97	17.99	7.16	121.95	295.33	4.35	3.17	17.99	7.52	121.95	296.1
Profit / (Loss) from ordinary activities after finance cost but before exceptional items (5-6)	21.79	301.82	665.86	323.61	1,037.47	748.00	-20.63	287.53	600.96	266.90	965.47	584.29
8 Exceptional items	0.00	0.00	0.00	0.00	0.00	-1,562.82	0.00	0.00	0.00	0.00	0.00	-1,552.82
9 Profit / (Loss) from ordinary activities before tax (7+8)	21.79	301.82	665.86	323.61	1,037.47	-804.82	-20.63	287.53	600.96	266.90	965.47	-968.53
10 Tax Expenses	2.00	0.00	133.84	2.00	207.91	2,105.00	2.00	0.00	133.84	2.00	207.91	2,105.00
11 Net Profit / (Loss) from ordinary activities after tax (9-10)	19.79	301.82	532.02	321.61	829.56	-2,909.82	-22.63	287.53	467.12	264.90	757.56	-3073.71
Extra Ordinary Items (net of tax expenses Rs. Lakhs)	0.00	0.00	0.00	0.00	0.00	10,704.79	0.00	0.00	0.00	0.00	0.00	10,704.79
13 Net Profit / (Loss) for the period (11+12)	19.79	301.82	532.02	321.61	829.56	7,794.97	-22.63	287.53	467.12	264.90	757.56	7631.08
14 Share of Profit / (Loss) of associates*												
15 Minority interest *												
Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15) *												
17 Paid-Up equity share capital	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18
(Face Value of the Share shall be indicated)												
Reserve excluding Revaluation Reserve as per Balance sheet of previous accounting year		NA	NA					NA	NA			
18.i Earnings per share (before extra ordinary items) (of Rs. 10 /-each) (not annualised):												
(a) Basic	0.15	2.28	4.02	2.43	6.27	-21.99	-0.17	2.17	3.52	1.99	5.72	-23.23
(b) Diluted	0.15	2.08	3.66	2.43	1.07	-21.99	-0.17	1.98	3.44	1.95	5.59	-23.23
19.i Earnings per share (after extra ordinary items) (of Rs. 10 /-each) (not annualised):												
(a) Basic	0.15	2.28	2.25	2.43	-1.07	58.90	-0.18	2.17	3.52	1.99	5.72	57.67
(b) Diluted	0.14	2.08	2.20	2.21	1.07	53.68	-0.18	1.98	3.44	1.95	5.59	52.55

See accompanying note to the financial results

For KILITCH DRUGS (INDIA) LTD.


DIRECTOR

PART II

	Particulars	STAND ALONE						CONSOLIDATED					
		30th September 2012	30th June 2012	30th September 2011	30th September 2012	30th September 2011	31st March 2012	30th September 2012	30th June 2012	30th September 2011	30th September 2012	30th September 2011	31st March 2012
A	PARTICULARS OF SHAREHOLDING												
1	Public shareholding												
	Number of shares	4706393	4706393	4706393	4706393	4706393	4706393	4706393	4706393	4706393	4706393	4706393	4706393
	Percentage of shareholding	35.57	35.57	35.57	35.57	35.57	35.57	35.57	35.57	35.57	35.57	35.57	35.57
2	Promoters and Promoter Group Shareholding **												
a)	Pledge / Encumbered												
	Number of shares												
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)												
	Percentage of shares (as a % of the total share capital of the company)												
b)	Non- encumbered												
	Number of shares	8525435	8525435	8525435	8525435	8525435	8525435	8525435	8525435	8525435	8525435	8525435	8525435
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
	Percentage of shares (as a % of the total share capital of the company)	64.43	64.43	64.43	64.43	64.43	64.43	64.43	64.43	64.43	64.43	64.43	64.43

Particulars	6 months ended 30TH SEPTEMBER 12
B INVESTOR COMPLAINTS	
Pending at the beginning of the year	NIL
Received during the half year	1
Disposed of during the half year	1
Remaining unresolved at the end of the half year	NIL

For KILITCH DRUGS (INDIA) LTD.

[Signature]

DIRECTOR

KILITCH DRUGS INDIA LIMITED
Standalone and Consolidated Statement of Assets and Liabilities

(Rupees in Lakhs)

		Stand Alone		Consolidated	
		Unaudited	Audited	Unaudited	Audited
		As at 30th September 2012	As at 31st March 2012	As at 30th September 2012	As at 31st March 2012
A	Statement of Assets and Liabilities				
	EQUITY AND LIABILITIES				
1	Shareholders Funds				
	(a) Share Capital	1,323.18	1,323.18	1,323.18	1,323.18
	(b) Reserve and Surplus	10,580.13	10,253.71	10,420.87	10,131.56
	Sub-total - Shareholders' Funds	11,903.31	11,576.89	11,744.05	11,454.74
2	Share application money pending allotment	0.00	0.00	0.00	0.00
3	Minority Interest*	0.00	0.00	88.10	107.75
4	Non-current liabilities				
	(a) Long-term borrowings	0.00	0.00	5.21	3.66
	(b) Deferred tax liabilities (net)	26.14	26.14	26.32	26.32
	(c) Long term provisions	27.31	37.03	27.31	51.83
	Sub Total-Non- current liabilities	53.45	63.17	58.84	81.81
5	Current liabilities				
	(a) Short-term borrowings	45.02	876.91	45.02	876.91
	(b) Trade Payables	1,219.22	478.61	1,238.18	365.90
	(c) Other current liabilities	567.79	124.98	571.00	133.37
	(d) Short- term provisions	381.67	4,644.78	413.50	4,871.00
	Sub Total- current liabilities	2,213.70	6,126.28	2,267.68	6,047.18
	TOTAL- EQUITY AND LIABILITIES	14,170.48	17,765.34	14,158.67	17,691.48
B	ASSETS				
1	Non-current assets				
	(a) Fixed Assets	781.76	847.24	797.62	884.45
	(b) Non-current investments	441.08	441.08	71.59	71.59
	(c) Long-term loans and advances	0.00	24.59	0.00	24.59
	Sub Total-Non- current assets	1,222.84	1,312.91	869.21	980.63
2	Current assets				
	(a) Current investments	9,935.99	13,577.37	10,148.37	13,758.50
	(b) Inventories	192.75	193.81	218.76	229.80
	(c) Trade receivables	1,578.80	1,447.19	1,669.47	1,503.20
	(d) Cash and cash equivalents	1,047.01	1,164.28	1,056.93	1,187.05
	(e) Short-term loans and advances	2.63	20.10	2.63	21.76
	(f) Other current assets	192.53	49.68	193.29	50.54
	Sub Total- current assets	12,947.82	16,452.43	13,289.46	16,730.86
	TOTAL A	14,170.48	17,765.34	14,158.67	17,691.48

See accompanying note to the financial results

*Applicable in the case of consolidated statement of assets and liabilities.

- Notes:
1. The above results after being reviewed by the audit committee have been approved and taken on record by the Board of Directors at its meeting held on 9th November 2012 and are subject to limited review by the auditors.
 2. The previous years/period figures have been regrouped and reclassified wherever required to conform with current year/period figures.
 3. The Company has only one primary reportable segment-Pharmaceuticals.
 4. During the previous year the Company has sold off its Paonta Sahib plant on a slump sale basis and the profit on such sale is shown under extra ordinary items as per Audited accounts as on 31/03/2012
 5. The results for current year are not comparable with the previous years result, since the Company has sold off its Paonta Sahib plant on 28/02/2012.

Place : Mumbai
Date: 9th November 2012

For KILITCH DRUGS (INDIA) LTD.

[Signature]
DIRECTOR



Kilitch Drugs (India) Ltd.

Admin. Off. : 37, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088.
• Tel. : +91-22-6121 4100 • Fax : +91-22-6703 1658
Regd. Off. : C-301/2, M.I.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705. Maharashtra
& Factory • Tel. : +91-22-6514 4185 / 2768 0913 • Fax : +91-22-2768 0912
• E-mail : info@kilitch.com • Website : www.kilitch.com

November 9, 2012

To,
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051.

Respected Sir,

Scrip Code: KILITCH

Sub: Limited Review Report for the quarter ended September 30 2012.

With reference to the captioned subject, we are enclosing herewith Limited Review Report for the quarter ended September 30, 2012 as received from the Statutory Auditors of the Company, M/s. RNR Iyer & Co, Chartered Accountants, Mumbai.

Kindly find the same in order and acknowledge the same.

Thanking You,

Yours faithfully,

For: **KILITCH DRUGS (INDIA) LIMITED**

**MUKUND MEHTA
MANAGING DIRECTOR**



Encl.a/a.



M/S R N R IYER & CO., Chartered Accountants.

No 10 Vaishak, 2B P.K.Road, Nahur, Mulund west, Mumbai – 400080.

Tel: 022-25643138, E-mail: rnriyerca@fastmail.fm

Review Report to the Board of Directors of M/s Kilitch Drugs India Limited

We have reviewed the accompanying statement of un-audited financial results of M/s. Kilitch Drugs India Limited for the quarter ended 30th September, 2012, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity issued by the Institute of the Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and, thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statements prepared in accordance with the Accounting Standards referred to in Section 211 (3C) of the Companies Act, 1956 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with Stock Exchanges including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s. R N R Iyer & Co.,

Chartered Accountants

Firm registration no 103786W


(Rajkumar Iyer)

(Proprietor)

Membership No 33964

Mumbai

Dated: 9th November, 2012

